BCL10 aberacije i aktivacija p65 gena NF-kappa B puta su odsutne ili retke u primarnom MALT limfomu želuca
Scindeks Asistent Scindeks Asistent
PDF (engleski)

Dopunski fajlovi

Bez naslova (engleski)
Bez naslova (engleski)
Bez naslova (engleski)
Bez naslova (engleski)

Kako citirati

1.
Hajder J, Marisavljević D, Stanisavljević N, Mihaljević B, Kovčin V, Marković O, i drugi. BCL10 aberacije i aktivacija p65 gena NF-kappa B puta su odsutne ili retke u primarnom MALT limfomu želuca. Vojnosanit Pregl [Internet]. 30. Oktobar 2014. [citirano 12. Juli 2026.];71(11). Dostupno na: https://asistent.ceon.rs/index.php/vsp/article/view/VSP130813035H

Sažetak

Uvod/Cilj. Limfomi limfnog tkiva pridruženog mukozi (MALT) čine 5–17% svih non-Hodgkin limfoma (NHL). Molekularna patogeneza MALT limfoma nije razjašnjena. Cilj ove studije bio je da se imunohistohemijski utvrdi prisustvo nuklearne koekspresije BCL10 i NF-kappaB (NF-κB) u tumorskim ćelijama želudačnog MALT limfoma kao i njihov uticaj na patogenezu i ishod bolesti. Metode. Analizirani su klinički podaci iz istorija bolesti 35 bolesnika sa novodijagnostikovanim želudačnim MALT limfomom i uzorci tkiva biopsije želuca bojeni su imunohistohemijskom metodom na ekspresiju BCL10 i NF-κB. Rezultati. Prosečna starost kod 35 bolesnika sa dijagnozom želudačnog MALT limfoma iznosila je 63,5 godina (muškarci/žene = 21/14). Simptomi su bili prisutni kod 23/35 (65,7%) bolesnika sa gubitkom težine kao najčešćim simptomom. Želudačni MALT limfom bio je najčešće lokalizovan u korpusu i korpusu i antrumu (45,7% i 31,2%). Infekcija H. pylori bila je potvrđena kod 20 od 30 (66,7%) bolesnika. Bolesnici su lečeni imunohemioterapijom (10 bolesnika, 28,5%), hirurški (9 bolesnika, 25,8%), kombinacijom hirurgije i hemioterapije (14 bolesnika, 40%) i suportivno (2 bolesnika, 5,7%). Kompletna remisija bila je postignuta kod 13 (37,1%) bolesnika, a parcijalna remisija kod dva (5,7%) bolesnika. Kod 16 (45,7%) bolesnika došlo je do progresije bolesti (p < 0,001). Citoplazmatska ekspresija BCL10 bila je nađena kod 19 (54,3%) tumorskih ćelija. Nuklearna ekspresija nije uočena ni u jednom uzorku. Citoplazmatska ekspresija NF-κB bila je prisutna u 22 (65,7%) uzorka, ali nuklearna ekspresija nije potvrđena ni u jednom uzorku. Zaključak. Nuklearna ekspresija (aktivacija) p65 subjedinice NF-κB puta i BCL10 nije otkrivena u uzorcima želudačnog MALT limfoma. Korelacija nuklearne koekspresije BCL10 i NF-κB u tumorskim ćelijama želudačnog MALT limfoma nije utvrđena. Ovi rezultati ukazuju da su neki drugi mehanizmi i signalni putevi aktivni u limfogenezi želudačnog MALT limfoma i da inhibicija apoptoze nije glavni i jedini mehanizam tumorogeneze.

Ključne reči

lymphoma
b-cell
marginal zone||
||limfom
malt
stomach neoplasms||
||želudac
neoplazme
immunohistochemistry||
||imunohistohemija
gene expression||
||geni
ekspresija
signal transduction||
||signali
transdukcija
DOI: 10.2298/2389

Reference

Harris NL, Jaffe ES, Diebold J, Flandrin G, Muller-Hermelink HK, Vardiman J, et al. World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: Report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997. J Clin Oncol 1999; 17(12): 3835−49.

Thieblemont C. Clinical presentation and management of mar-ginal zone lymphomas. Hematology Am Soc Hematol Educ Program 2005: 307−13.

Ferrucci PF, Zucca E. Primary gastric lymphoma pathogenesis and treatment: what has changed over the past 10 years. Br J Haematol 2007; 136(4): 521−38.

Pozzi B, Cerati M, Capella C. MALT lymphoma: pathology. In: Bertoni F, Zucca E editor. MALT lymphomas. Georgetown (TX): Landes Bioscience/Kluwer Plenum Publishers; 2004. p. 17−38.

Thieblemont C, Coffier B. MALT lymphomas. Sites of Presenta-tions, Clinical features and Staging Procedures. In: : Bertoni F, Zucca E editor. MALT lymphomas. Georgetown (TX): Landes Bioscience/Kluwer Plenum Publishers; 2004. p. 60−80.

Katić V, Katić K, Vučetić M, Gligorijević J. The histopathology and immunohistology of gastric MALT lymphoma. Arch Oncol 2004; 12(1): 5−6.

Kahl BS. Update: gastric MAcLT lymphoma. Curr Opin Oncol 2003; 15: 347−52.

Nakagawa M, Hosokawa Y, Yonezumi M, Izumiyama K, Suzuki R, Tsuzuki S, et al. MALT1 contains nuclear export signals and regulates cytoplasmic localization of BCL10. Blood 2005; 106(13): 4210−6.

Hachem A, Gartenhaus RB. Oncogenes as molecular targets in lymphoma. Blood 2005; 106(6): 1911−23.

Bugarski D, Petakov M, Vlaški M, Krstić A, Čokić V, Jovčić G, et al.. Mehanizmi prenosa signala u toku stimulacije matičnih ćelija hematopoeze. Bilten za hematologiju 2004; 32(3): 156−9. (Serbian)

Lucas PC, Yonezumi M, Inohara N, Mcallister-Lucas LM, Abazeed ME, Chen FF, et al. Bcl10 and MALT1, Independent Targets of Chromosomal Translocation in MALT Lymphoma, Cooperate in a Novel NF-kappa B Signaling Pathway. J Biol Chem 2001; 276(22): 19012−9.

Isaacson PG, Du M. MALT lymphoma: from morphology to molecules. Nat Rev Cancer 2004; 4(8): 644−53.

Ye H, Gong L, Liu H, Hamoudi RA, Shirali S, Ho L, et al.. MALT lymphoma with t(14;18)(q32;q21)/IGH-MALT1 is characterized by strong cytoplasmic MALT1 and BCL10 ex-pression. J Pathol 2005; 205(3): 293−301.

Bertoni F, Cotter F. MALT lymphomas. Genetics and Biology. In: Bertoni F, Zucca E editor. MALT lymphomas. Georgetown (TX): Landes Bioscience/Kluwer Plenum Publishers; 2004. p. 46−59.

Ye H, Dogan A, Karran L, Willis TG, Chen L, Wlodarska I, et al. BCL10 Expression in Normal and Neoplastic Lymphoid Tis-sue: Nuclear localisation in MALT lymphoma. Am J Pathol 2000; 157(4): 1147−54.

Cavalli F, Isaacson PG, Gascoyne RD, Zucca E. MALT Lympho-mas. Hematology Am Soc Hematol Educ Program 2001: 241−58.

Lui H, Ye H, Dogan A, Ranaldi R, Hamoudi RA, Bearzi I, et al. T(11;18)(q21;q21) is associated with advanced mucosa-associated lymphoid tissue lymphoma that expresses nuclear BCL10. Blood 2001; 98(4): 1182−7.

Yeh KH, Kuo SH, Chen LT, Mao TL, Doong SL, Wu MS, et al. Nuclear expression of BCL10 or nuclear factor kappa B helps predict Helicobacter pylori-independent status of low-grade gastric mucosa-associated lymphoid tissue lymphomas with or without t(11;18)(q21;q21). Blood 2005; 106(3): 1037−41.

Franco R, Camacho FI, Caleo A, Staibano S, Bifano D, de Renzo A, et al. Nuclear bcl10 expression characterizes a group of ocular adnexa MALT lymphomas with shorter failure-free survival. Mod Pathol 2006; 19(8): 1055−67.

Gilmore TD, Kalaitzidis D, Liang MC, Starczynowski DT. The c-Rel transcription factor and B-cell proliferation: a deal with the devil. Oncogene 2004; 23(13): 2275−86.

Talwalkar SS, Valbuena JR, Abruzzo LV, Admirand JH, Konoplev SN, Bueso-Ramos CE, et al. MALT1 gene rerrangements and NF-kappaB activation involving p65 and p50 are absent or rare in primary MALT lymphomas of the breast. Mod Pathol 2006; 19(11): 1402−8.

Sagaert X, Laurent M, Baens M, Wlodarska I, de Wolf-Peeters C. MALT1 and BCL10 aberrations in MALT lymphomas and their effect on the expression of BCL10 in the tumour cells. Mod Pathol 2006; 19(2): 225−32.

Sagaert X, de Wolf-Peeters C, Noels H, Baens M. The pathogenesis of MALT lymphomas: where do we stand. Leukemia 2007; 21(3): 389−96.